1. Abelson JL, Nesse RM. Cholecystokinin-4 and panic. Arch Gen Psychiatry 1990;47:395.

2. Andrews N, File SE. Are there changes in sensitivity to 5-HT3 receptor ligands following chronic diazepam treatment? Psychopharmacology 1992;108:333–337.

3. Ansseau M, Olie JP, von Frenckell R, et al. Controlled comparisons of the efficacy and safety of four doses of suriclone, diazepam and placebo in generalized anxiety disorder. Psychopharmacology 1991;104:439–443.

4. Applebaum PS. Controlling prescriptions of benzodiazepines. Hosp Community Psychiatry 1992;43:12–13.

5. Argyle N. Panic attacks in chronic schizophrenia. Br J Psychiatry 1990;157:430–433.

6. Aronson TA. A naturalistic study of imipramine in panic disorder and agoraphobia. Am J Psychiatry 1987;144:1014–1019.

7. Ballenger JC, McDonald S, Noyes R, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112–119) in generalized anxiety disorder. Psychopharmacol Bull 1991;27:171–179.

8. Balter MB, Ban TA, Uhlenhuth EH. International study of expert judgment on the therapeutic use of benzodiazepines and other psychotherapeutic medications. I. Current concerns. Hum Psychopharmacol 1993;8:253–261.

9. Beinfeld MC. Cholecystokinin in the central nervous system: a mini review. Neuropeptide 1983;3:411–427.

10. Berner R. The patient's perspective. N Y State J Med 1991; 91(11)(suppl):37S–39S.

11. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44–50.

12. Blackburn TP. 5-HT receptors and anxiolytic drugs. In: Marsden CA, Heal DJ, eds. Central serotonin receptors and psychotropic drugs. London: Blackwell Scientific Publishers, 1992;175–197.

13. Borison RL, Albrecht JW, Diamond BI. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 1990;26:207–210.

14. Bouthillier A, de Montigny C. Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat. Eur J Pharmacol 1988;151:135–138.

15. Bradwejn J, de Montigny C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature 1984;313:363–364.

16. Bradwejn J, de Montigny C. Antagonism of cholecystokinininduced activation by benzodiazepine receptor agonists. Ann NY Acad Sci 1985;448:575–580.

17. Bradwejn J, Koszycki J, Payeur R, et al. Replication of action of cholecystokinin tetrapeptide in panic disorder patients. In: New research program and abstracts of the 144th meeting of the American Psychiatric Association, May 11–16, 1991, New Orleans, LA, Abstract NR367.

18. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 1991;48:603–610.

19. Bradwejn J, Koszycki D, Payeur R, et al. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 1992;149:962–964.

20. Brady K, Zarzar M, Lydiard RB. Fluoxetine in panic disorder patients with imipramine-associated weight gain. J Clin Psychopharmacol 1989;9:66–67.

21. Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorders. I. the first 10 weeks of a long-term comparison with imipramine. J Affect Dis 1988;14:123–127.

22. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512–1517.

23. Costall B. The breadth of action of the 5-HT3 receptor antagonists. Int Clin Psychopharmacol 1993;8(suppl 2):3–9.

24. Costall B, Naylor RJ. Anxiolytic potential of 5-HT3 receptor antagonists. Pharmacol Toxicol 1992;70:157–162.

25. Cross-national collaborative panic study second phase investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992;160:191–202.

26. Csonka E, Fekete M, Nagy G, et al. Anxiogenic effect of cholecystokinin in rats. In: Penke B, Torok A, eds. Peptides. New York: Walter de Gruyter & Co, 1988;249–252.

27. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings. Arch Gen Psychiatry 1989;46:511–517.

28. den Boer JA, Westenberg HGM. Effect of serotonin and noradrenaline uptake inhibitors in panic disorder; a double blind comparative study with fluvoxamine and maprotiline. Int J Clin Pharmacol 1988;3:59–74.

29. den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102:85–94.

30. den Boer JA, Westenberg HGM, Kamerbeek WDJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders; a double blind comparison of clomipramine and fluvoxamine. Int J Psychopharmacol 1987;2:21–32.

31. Doble A, Canton T, Dreisler S, et al. RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. interaction with the g-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent. J Pharmacol Exp Ther 1993;266:1213–1226.

32. Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986;47:458–460.

33. Fischer V, Vickers AEM, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos Biol Fate Chem 1994;22:269–274.

34. Fleishaker JC, Friedman H, Pollock SR, et al. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteers. Clin Pharmacol Ther 1990;48:652–664.

35. Fleishaker JC, Smith TC, Friedman H, et al. N-Desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10–50 mg oral doses in healthy volunteers. Psychopharmacol 1991;105:181–185.

36. Fleishaker JC, Hulst LK. Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of alprazolam in healthy volunteers. Pharmacol Res 1992;9:294.

37. Fleishaker JC, Greist JH, Jefferson JW, et al. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:28–35.

38. Goddard AW, Woods SW, Scholomskas DE, et al. Effect of the serotonin uptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;8:119–133.

39. Gorman JM, Liebowitz MR, Fyer AJ. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329–332.

40. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs the clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479–486.

41. Haefely W, Martin JR, Schoch P: Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 1990;11:452–456.

42. Harrington MA, Zhong P, Garlow SJ, et al. Molecular biology of serotonin receptors. J Clin Psychiatry 1992;53(suppl 10):8–27.

43. Hendrie CA, Dourish CT. Anxiolytic profile of the cholecystokinin antagonist devazepide in mice. Br J Pharmacol 1990;99(suppl):138.

44. Higgins GA, Jones BJ, Oakley NR, et al. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology 1991;104:545–551.

45. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic vs psychic symptoms. J Clin Psychiatry 1988;49:293–301.

46. Hoehn-Saric R, McLeod DR, Hipsley PA. Effects of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321–326.

47. Hollister LE, Müller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993;13(suppl 1):1S–169S.

48. Hoyer D, Boddeke HWGM. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 1993;14:270–275.

49. Jann MW, Kurtz NM. Treatment of panic and phobic disorders. Clin Pharmacol 1987;6:947–962.

50. Jann MW. Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy 1988;8:100–116.

51. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:453–459.

52. Jones BJ, Costall B, Domeney AM, et al. The potential anxiolytic activity of GR38032F, a 5-HT3 receptor antagonist. Br J Pharmacol 1988;93:985–993.

53. Julou L, Blanchard JC, Dreyfus JF. Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav 1985;23:653–659.

54. Katshnig H. Attack-related treatment of panic disorder with bretazenil. Biol Psychiatry 1991;29:59S.

55. Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochromes P450 IIIA4. Mol Pharmacol 1989;36:89–96.

56. Lader MH. Ondansetron in the treatment of anxiety. From a satellite symposium at the 5th World Congress of Biological Psychiatry, Florence, Italy, June 9, 1991, pp. 16–19.

57. Lasagna L, Shader RI. A white paper on the appropriateness of proposals by the FDA to modify the labeling of benzodiazepine sedative-hypnotics. J Clin Pharmacol 1994;34:812–815.

58. Lasher TA, Fleishaker JC, Steenwyk RC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104:323–327.

59. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990;81:185–189.

60. Lydiard RB, Ballenger JC, Laraia MT, et al. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 1992;149:691–693.

61. Maddock RJ, Carter CS, Blacker KH, et al. Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. J Clin Psychiatry 1993;54:88–95.

62. Martin JR, Pieri L, Bonetti EP, et al. Ro16-608: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 1988;21:360–362.

63. Mavissakalian MR, Perel JM. Imipramine dose–response relationship in panic disorder with agoraphobia: preliminary findings. Arch Gen Psychiatry 1989;46:127–131.

64. Millington WR, Mueller GP, Lavigne GJ. Cholecystokinin type A and type B receptor antagonists produced opposing effects on cholecystokinin-stimulated b-endorphin secretion from the rat pituitary. J Pharmacol Exp Ther 1992;261:454–461.

65. Modigh K. Antidepressants in anxiety disorders. Acta Psychiatr Scand 1987;76(suppl 335):57–71.

66. Morselli PL. On the therapeutic action of alpidem in anxiety disorders: an overview of European data. Pharmacopsychiatry 190;23(suppl 2):129–135.

67. Morton S, Lader M. Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects. Pharmacopsychiatry 1992;25:177–181.

68. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989;9:22–27.

69. Pohl R, Yeragani VK, Balon R, et al. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100–104.

70. Pyke RE, Greenberg HS. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989;9:15–21.

71. Ravard S, Dourish CT. Cholecystokinin and anxiety. Trends Pharmacol Sci 1990;11:271–273.

72. Reidenberg MM. Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State. Clin Pharmacol Ther 1991;50:129–131.

73. Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacology 1990;10:119–121.

74. Schwartz HI. Negative clinical consequences of triplicate prescription regulation of benzodiazepines. New York State J Med 1991;91(11)(suppl 11):9S–12S.

75. Schwartz HI. An empirical review of the impact of triplicate prescription of benzodiazepines. Hosp Community Psychiatry 1992;43:382–385.

76. Schwartz HI, Blank K. Regulation of benzodiazepine prescribing practices: clinical implications. Gen Hosp Psychiatry 1991;13:219–224.

77. Schweizer E, Fox I, Case G, et al. Lorazepam versus alprazolam in the treatment of panic disorder. Psychopharmacol Bull 1988;24:224–227.

78. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398–1405.

79. Shader RI, Greenblatt DJ. Approaches to the treatment of anxiety. In: Shader RI, ed. Manual of psychiatric therapeutics. Boston: Little, Brown and Co, 1994;275–298.

80. Shader RI, Greenblatt DJ, Balter MB. Appropriate use and regulatory control of benzodiazepines. J Clin Pharmacol 1991;31:781–784.

81. Sheehan DV, Raj AB, Harnett Sheehan K, et al. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 1988;29:815–817.

82. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. Adinazolam sustained release formulation in the treatment of panic disorder. Ir J Psychol Med 1990;7:124–128.

83. Solyom L, Solyom C, Ledwidge B. Fluoxetine in panic disorder. Can J Psychiatry 1991;36:378–379.

84. Stephens DN, Schneider HH, Kehr W, et al. Abecarnil, a metabolically stable anxioselective b-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 1990;253:334–343.

85. Stephenson FA, Duggan MJ, Pollard S: The g2 subunit is an integral component of the g-aminobutyric acidA receptor but the a1 polypeptide is the principal site of the agonist benzodiazepine photoaffinity labeling reaction. J Biol Chem 1990;265:21160–21165.

86. Taylor CB, Hayward C, King R, et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 1990;10:112–118.

87. Tesar GE, Rosenbaum JF, Pollack MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987;48(suppl):S16–S19.

88. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268–276.

89. Wafford KA, Bain CJ, Whiting PJ, et al. Functional comparison of the role of g subunits in recombinant human g-aminobutyric acidA/benzodiazepine receptors. Mol Pharmacol 1993;44:437–442.

90. Warot D, Bergougnan L, Lamiable D, et al. Troleandomycin–triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987;32:389–393.

91. Weintraub M, Singh S, Byrne L, et al. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991;266:2392–2397.

92. Westenberg HGM, den Boer JA. Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacol Bull 1989;25:119–123.

93. Wilkinson G, Balestrieri M, Ruggeri M, et al: Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychol Med 1991;21:991–998.

94. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992;44:151–347.

95. Wright CE, Lasher-Sisson TA, Steenwyk RC, et al. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103–106.

96. Zullich SG, Grasela TH, Fiedler-Kelly JB, et al: Impact of triplicate prescription programs on psychotropic prescribing patterns in long-term care facilities. Ann Pharmacother 1992;26:539–546.

97. Zundel JL, Blanchard JC, Julou L. Partial chemical characterization of cyclopyrrolones ([3H]-suriclone) and benzodiazepines ([3H]-flunitrazepam) binding site: differences. Life Sci 1985;36:2247–2255.